A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments. All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as an intravesical infusion, which means it will be injected directly into the bladder. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin. For all parts, treatment with study medicines will continue until either a participant has decided to stop taking part in the study or is asked to leave the study for various reasons or up to about 2 years, whichever occurs first. Duration of trial participation for each participant will vary as long-term follow-up will continue after treatment discontinuation until loss to-follow-up or death, or until the study is stopped by the sponsor.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Rozpoznanie raka pęcherza moczowego (wysoki stopień zaawansowania, bez rozprzestrzeniania się w głębokie warstwy)
- •Choroba oporná na leczenie BCG lub powrót raka po leczeniu BCG
- •Odmowa lub brak możliwości poddania się usunięciu pęcherza
- •Dostęp do próbki guza sprzed ostatnich 6 miesięcy
- •Dobry ogólny stan zdrowia (ECOG 0 lub 1)
✗ Disqualifies
- •Jednoczesne otrzymywanie innych leków na raka pęcherza lub wcześniejsza radioterapia pęcherza
- •Poważne problemy z wątrobą, nerkami lub zaburzenia krwi
- •Aktywna, niekontrolowana infekcja
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (68)
The Kirklin Clinic of UAB Hospital
Birmingham, United States
UAB Infusion Therapy Extended Care Clinic (ECC)
Birmingham, United States
The University of Alabama at Birmingham Investigation Drug Services Pharmacy
Birmingham, United States
University of Alabama at Birmingham
Birmingham, United States
Moffitt Cancer Center at SouthShore
Ruskin, United States
Moffitt Cancer Center - International Plaza
Tampa, United States
Moffitt Cancer Center - McKinley Campus
Tampa, United States
Moffitt Cancer Center
Tampa, United States
Moffitt McKinley Hospital
Tampa, United States
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, United States
Emory University Hospital Midtown
Atlanta, United States
Emory University Hospital
Atlanta, United States
Emory University
Atlanta, United States
Northwestern Memorial Hospital
Chicago, United States
Northwestern University - Feinberg School of Medicine
Chicago, United States
University of Iowa Health Care
Iowa City, United States
The University of Kansas - Clinical Research Center
Fairway, United States
The University of Kansas Hospital Cambridge North Tower A
Kansas City, United States
The University of Kansas Hospital
Kansas City, United States
The University of Kansas Medical Center Medical Office Building
Kansas City, United States
The University of Kansas Hospital - Indian Creek Campus
Overland Park, United States
The University of Kansas Cancer Center - Westwood
Westwood, United States
MSK Basking Ridge
Basking Ridge, United States
MSK Monmouth
Middletown, United States
MSK Bergen
Montvale, United States
MSK Commack
Commack, United States
MSK Westchester
Harrison, United States
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, United States
Memorial Sloan Kettering Cancer Center 53rd street
New York, United States
Icahn School of Medicine at Mount Sinai
New York, United States
64th Street Outpatient and Innovation Center
New York, United States
Memorial Sloan Kettering Cancer Center - Main Campus
New York, United States
Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center
New York, United States
Upstate Specialty Services at Harrison Center
Syracuse, United States
SUNY Upstate Medical University
Syracuse, United States
SUNY Upstate Medical University-Community Campus
Syracuse, United States
MSK Nassau
Uniondale, United States
Biorepository and Precision Pathology Center (BRPC)
Durham, United States
Duke Cancer Institute
Durham, United States
Substrate Services Core Research Support (SSCRS)
Durham, United States
Grand Strand Medical Center
Myrtle Beach, United States
AUC Urologists, LLC
Myrtle Beach, United States
Carolina Urologic Research Center, LLC
Myrtle Beach, United States
Parkway Surgery Center
Myrtle Beach, United States
Coastal Eye Group
Myrtle Beach, United States
Urology Associates, P.C.
Nashville, United States
Cancer Center Outpatient Building
Dallas, United States
The University of Texas Southwestern Medical Center
Dallas, United States
UT Southwestern Medical Center - West Campus Building
Dallas, United States
UT Southwestern Medical Center - William P Clements Jr University Hospital
Dallas, United States
UT Southwestern Medical Center-William P. Clements Imaging Center
Dallas, United States
Baptist M&S Imaging (Medical Center)
San Antonio, United States
USA Clinical Trials
San Antonio, United States
MCOA Eye Associates
San Antonio, United States
Gustave Roussy
Villejuif, France
Pitie Salpetriere University Hospital
Paris, France
Rabin Medical Center
Petah Tikva, Israel
Sheba Medical Center
Ramat Gan, Israel
Hadassah Medical Center
Jerusalem, Israel
Rambam Health Care Campus
Haifa, Israel
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Hospital Universitario 12 de Octubre
Madrid, Spain
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
Royal Hallamshire Hospital
Sheffield, United Kingdom
The University of Sheffield
Sheffield, United Kingdom
Weston Park Cancer Centre
Sheffield, United Kingdom
Trial contact
Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.